Report error Found 56 Enz. Inhib. hit(s) with all data for entry = 10902
Affinity DataIC50: 4nMAssay Description:The activity on human GSK-3β of the compounds of the invention listed in the following Table 1 and of the comparison compound C was assessed at ...More data for this Ligand-Target Pair
Affinity DataIC50: 4.5nMAssay Description:The activity on human GSK-3β of the compounds of the invention listed in the following Table 1 and of the comparison compound C was assessed at ...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:The activity on human GSK-3β of the compounds of the invention listed in the following Table 1 and of the comparison compound C was assessed at ...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:The activity on human GSK-3β of the compounds of the invention listed in the following Table 1 and of the comparison compound C was assessed at ...More data for this Ligand-Target Pair
Affinity DataIC50: 12nMAssay Description:The activity on human GSK-3β of the compounds of the invention listed in the following Table 1 and of the comparison compound C was assessed at ...More data for this Ligand-Target Pair
Affinity DataIC50: 13nMAssay Description:The activity on human GSK-3β of the compounds of the invention listed in the following Table 1 and of the comparison compound C was assessed at ...More data for this Ligand-Target Pair
Affinity DataIC50: 14nMAssay Description:The activity on human GSK-3β of the compounds of the invention listed in the following Table 1 and of the comparison compound C was assessed at ...More data for this Ligand-Target Pair
Affinity DataIC50: 14nMAssay Description:The activity on human GSK-3β of the compounds of the invention listed in the following Table 1 and of the comparison compound C was assessed at ...More data for this Ligand-Target Pair
Affinity DataIC50: 15nMAssay Description:The activity on human GSK-3β of the compounds of the invention listed in the following Table 1 and of the comparison compound C was assessed at ...More data for this Ligand-Target Pair
Affinity DataIC50: 16nMAssay Description:The activity on human GSK-3β of the compounds of the invention listed in the following Table 1 and of the comparison compound C was assessed at ...More data for this Ligand-Target Pair
Affinity DataIC50: 17nMAssay Description:The activity on human GSK-3β of the compounds of the invention listed in the following Table 1 and of the comparison compound C was assessed at ...More data for this Ligand-Target Pair
Affinity DataIC50: 17nMAssay Description:The activity on human GSK-3β of the compounds of the invention listed in the following Table 1 and of the comparison compound C was assessed at ...More data for this Ligand-Target Pair
Affinity DataIC50: 17nMAssay Description:The activity on human GSK-3β of the compounds of the invention listed in the following Table 1 and of the comparison compound C was assessed at ...More data for this Ligand-Target Pair
Affinity DataIC50: 18.5nMAssay Description:The activity on human GSK-3β of the compounds of the invention listed in the following Table 1 and of the comparison compound C was assessed at ...More data for this Ligand-Target Pair
Affinity DataIC50: 20nMAssay Description:The activity on human GSK-3β of the compounds of the invention listed in the following Table 1 and of the comparison compound C was assessed at ...More data for this Ligand-Target Pair
Affinity DataIC50: 21.6nMAssay Description:The activity on human GSK-3β of the compounds of the invention listed in the following Table 1 and of the comparison compound C was assessed at ...More data for this Ligand-Target Pair
Affinity DataIC50: 22nMAssay Description:The activity on human GSK-3β of the compounds of the invention listed in the following Table 1 and of the comparison compound C was assessed at ...More data for this Ligand-Target Pair
Affinity DataIC50: 23nMAssay Description:The activity on human GSK-3β of the compounds of the invention listed in the following Table 1 and of the comparison compound C was assessed at ...More data for this Ligand-Target Pair
Affinity DataIC50: 26nMAssay Description:The activity on human GSK-3β of the compounds of the invention listed in the following Table 1 and of the comparison compound C was assessed at ...More data for this Ligand-Target Pair
Affinity DataIC50: 28nMAssay Description:The activity on human GSK-3β of the compounds of the invention listed in the following Table 1 and of the comparison compound C was assessed at ...More data for this Ligand-Target Pair
Affinity DataIC50: 32nMAssay Description:The activity on human GSK-3β of the compounds of the invention listed in the following Table 1 and of the comparison compound C was assessed at ...More data for this Ligand-Target Pair
Affinity DataIC50: 33nMAssay Description:The activity on human GSK-3β of the compounds of the invention listed in the following Table 1 and of the comparison compound C was assessed at ...More data for this Ligand-Target Pair
Affinity DataIC50: 49.9nMAssay Description:Confirmation of interaction with the potassium channels of the compounds of the invention listed in the following Table 1 and of the comparison compo...More data for this Ligand-Target Pair
Affinity DataIC50: 55nMAssay Description:The activity on human GSK-3β of the compounds of the invention listed in the following Table 1 and of the comparison compound C was assessed at ...More data for this Ligand-Target Pair
Affinity DataIC50: 120nMAssay Description:The activity on human GSK-3β of the compounds of the invention listed in the following Table 1 and of the comparison compound C was assessed at ...More data for this Ligand-Target Pair
Affinity DataIC50: 130nMAssay Description:The activity on human GSK-3β of the compounds of the invention listed in the following Table 1 and of the comparison compound C was assessed at ...More data for this Ligand-Target Pair
Affinity DataIC50: 140nMAssay Description:The activity on human GSK-3β of the compounds of the invention listed in the following Table 1 and of the comparison compound C was assessed at ...More data for this Ligand-Target Pair
Affinity DataIC50: 220nMAssay Description:The activity on human GSK-3β of the compounds of the invention listed in the following Table 1 and of the comparison compound C was assessed at ...More data for this Ligand-Target Pair
Affinity DataIC50: 436nMAssay Description:The activity on human GSK-3β of the compounds of the invention listed in the following Table 1 and of the comparison compound C was assessed at ...More data for this Ligand-Target Pair
Affinity DataIC50: 860nMAssay Description:Confirmation of interaction with the potassium channels of the compounds of the invention listed in the following Table 1 and of the comparison compo...More data for this Ligand-Target Pair
Affinity DataIC50: 3.50E+3nMAssay Description:Confirmation of interaction with the potassium channels of the compounds of the invention listed in the following Table 1 and of the comparison compo...More data for this Ligand-Target Pair
Affinity DataIC50: 4.00E+3nMAssay Description:Confirmation of interaction with the potassium channels of the compounds of the invention listed in the following Table 1 and of the comparison compo...More data for this Ligand-Target Pair
Affinity DataIC50: 4.30E+3nMAssay Description:Confirmation of interaction with the potassium channels of the compounds of the invention listed in the following Table 1 and of the comparison compo...More data for this Ligand-Target Pair
Affinity DataIC50: 5.40E+3nMAssay Description:Confirmation of interaction with the potassium channels of the compounds of the invention listed in the following Table 1 and of the comparison compo...More data for this Ligand-Target Pair
Affinity DataIC50: 5.50E+3nMAssay Description:Confirmation of interaction with the potassium channels of the compounds of the invention listed in the following Table 1 and of the comparison compo...More data for this Ligand-Target Pair
Affinity DataIC50: 5.70E+3nMAssay Description:Confirmation of interaction with the potassium channels of the compounds of the invention listed in the following Table 1 and of the comparison compo...More data for this Ligand-Target Pair
Affinity DataIC50: 6.20E+3nMAssay Description:Confirmation of interaction with the potassium channels of the compounds of the invention listed in the following Table 1 and of the comparison compo...More data for this Ligand-Target Pair
Affinity DataIC50: 6.70E+3nMAssay Description:Confirmation of interaction with the potassium channels of the compounds of the invention listed in the following Table 1 and of the comparison compo...More data for this Ligand-Target Pair
Affinity DataIC50: 1.10E+4nMAssay Description:Confirmation of interaction with the potassium channels of the compounds of the invention listed in the following Table 1 and of the comparison compo...More data for this Ligand-Target Pair
Affinity DataIC50: 1.30E+4nMAssay Description:Confirmation of interaction with the potassium channels of the compounds of the invention listed in the following Table 1 and of the comparison compo...More data for this Ligand-Target Pair
Affinity DataIC50: 1.50E+4nMAssay Description:Confirmation of interaction with the potassium channels of the compounds of the invention listed in the following Table 1 and of the comparison compo...More data for this Ligand-Target Pair
Affinity DataIC50: 1.60E+4nMAssay Description:Confirmation of interaction with the potassium channels of the compounds of the invention listed in the following Table 1 and of the comparison compo...More data for this Ligand-Target Pair
Affinity DataIC50: 1.90E+4nMAssay Description:Confirmation of interaction with the potassium channels of the compounds of the invention listed in the following Table 1 and of the comparison compo...More data for this Ligand-Target Pair
Affinity DataIC50: 2.20E+4nMAssay Description:Confirmation of interaction with the potassium channels of the compounds of the invention listed in the following Table 1 and of the comparison compo...More data for this Ligand-Target Pair
Affinity DataIC50: 4.00E+4nMAssay Description:Confirmation of interaction with the potassium channels of the compounds of the invention listed in the following Table 1 and of the comparison compo...More data for this Ligand-Target Pair
Affinity DataIC50: 4.10E+4nMAssay Description:Confirmation of interaction with the potassium channels of the compounds of the invention listed in the following Table 1 and of the comparison compo...More data for this Ligand-Target Pair
Affinity DataIC50: 4.40E+4nMAssay Description:Confirmation of interaction with the potassium channels of the compounds of the invention listed in the following Table 1 and of the comparison compo...More data for this Ligand-Target Pair
Affinity DataIC50: 4.60E+4nMAssay Description:Confirmation of interaction with the potassium channels of the compounds of the invention listed in the following Table 1 and of the comparison compo...More data for this Ligand-Target Pair
Affinity DataIC50: 4.70E+4nMAssay Description:Confirmation of interaction with the potassium channels of the compounds of the invention listed in the following Table 1 and of the comparison compo...More data for this Ligand-Target Pair
Affinity DataIC50: 4.90E+4nMAssay Description:Confirmation of interaction with the potassium channels of the compounds of the invention listed in the following Table 1 and of the comparison compo...More data for this Ligand-Target Pair
